Statements of Stockholders' Equity - USD ($)	Series A Warrants [Member] Common Stock [Member]	Series A Warrants [Member] Additional Paid-in Capital [Member]	Series A Warrants [Member]	Series B Warrants [Member] Common Stock [Member]	Series B Warrants [Member] Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member] Common Stock [Member]	Investment Banker [Member] Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member] Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member] Common Stock [Member]	Former CEO [Member] Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member] Common Stock [Member]	The 2016 Registered Direct Offering [Member] Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																																				$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																																					208,259
Shares issued for two options exercised at $65.75 per share (in shares)																																					1,312
Shares issued for two options exercised at $65.75 per share																																					$ 13	86,240			86,253
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering																																				(18,158)	$ 664	17,494			0
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares)																																					66,396
Shares issued for cashless warrant exercises (in shares)	2,318,663			628,237
Shares issued for cashless warrant exercises	$ 23,187	$ 556,479	$ 579,666	$ 6,282	$ 150,777	$ 157,059
Shares issued for services (in shares)							135,995
Shares issued for services							$ 1,360	$ 508,620	$ 509,980
Shares Issued (in shares)										26,000			400,000		20,000			756,999
Shares Issued										$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Vesting Expense																																						165,271			165,271
Unrealized gain from marketable securities																																								$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																																					2,567
Corrections due to rounding for reverse split and DTCC increase																																					$ 28	(29)			(1)
Net loss																																							(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																																				792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																					4,564,428
Shares issued for services (in shares)																								100,000			43,333			50,000
Shares issued for services																								$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132	$ 500	$ 78,500	$ 79,000
Shares Issued (in shares)																					175,000																1,750,000
Shares Issued																					$ 1,750	$ 392,000	$ 393,750										$ 12,138	$ 1,201,681	$ 1,213,819		$ 17,500	3,403,688			3,421,188
Vesting Expense																																						4,042,256			4,042,256
Unrealized gain from marketable securities																																							(1)	$ (1,501)
Net loss																																							(7,746,593)		(7,746,593)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																					(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																					$ (4,000)				(4,000)
Preferred conversion to common shares pursuant to a private placement agreement																																				(5,659)	$ 6,604	85,236			86,182
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																					660,522
Balance at Dec. 31, 2017																																				$ 7,271	$ 69,432	$ 57,380,256	$ (54,765,045)		$ 2,691,914
Balance (in shares) at Dec. 31, 2017																																					6,943,283